Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024.

IF 5.5 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2024-09-11 DOI:10.1080/14760584.2024.2401839

Mario Rivera-Izquierdo,Arturo Morales-Portillo,Inmaculada Guerrero-Fernández de Alba,Nicolás Francisco Fernández-Martínez,Joan Antoni Schoenenberger-Arnaiz,José Luis Barranco-Quintana,Carmen Valero-Ubierna

{"title":"Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024.","authors":"Mario Rivera-Izquierdo,Arturo Morales-Portillo,Inmaculada Guerrero-Fernández de Alba,Nicolás Francisco Fernández-Martínez,Joan Antoni Schoenenberger-Arnaiz,José Luis Barranco-Quintana,Carmen Valero-Ubierna","doi":"10.1080/14760584.2024.2401839","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\r\nMonoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules.\r\n\r\nAREAS COVERED\r\nVaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies.\r\n\r\nEXPERT OPINION\r\nCurrent recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, that are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2401839","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules. AREAS COVERED Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies. EXPERT OPINION Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, that are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.

查看原文本刊更多论文

单克隆抗体和其他生物治疗患者的疫苗接种策略：根据截至 2024 年 1 月的 EMA 授权进行的最新全面审查。

简介近年来，越来越多的单克隆抗体（mAbs）和其他生物制剂被批准用于不同的适应症。它们的免疫抑制作用、作用机制和药代动力学各不相同，因此需要制定全面的个体化疫苗接种计划。专家观点目前针对接受 mAbs 或其他生物治疗的患者的疫苗接种计划建议是基于专家意见，并没有根据每种疫苗和治疗方法进行个体化。没有任何研究关注这些制剂的高度异质性，这些制剂被成倍地开发并用于许多不同的适应症。在过去几年中，疫苗开发（受 COVID-19 大流行的推动）和用于预防目的的 mAbs（将 "疫苗接种 "改为 "免疫接种"）的模式发生了最新变化。我们的目标是收集截至 2024 年 1 月 1 日由 EMA 批准的所有用于治疗或预防的 mAbs。根据现有的 mAbs 和疫苗数据，我们提出了个性化疫苗接种的综合指南。其中讨论了疫苗的最新发展和当前的人群策略（如带状疱疹疫苗接种或预防性的 nirsevimab）。本综述旨在为从事免疫抑制患者疫苗咨询工作的专业人员提供实用指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.